<DOC>
	<DOCNO>NCT00638976</DOCNO>
	<brief_summary>Randomized , blind control , Multicenter , spontaneous , prospective trial , roughly 20 enrol center Italy , placebo active drug supply give GlaxoSmithKline ( GSK ) .</brief_summary>
	<brief_title>INSTANT : INtegrilin Plus STenting Avoid Myocardial Necrosis Trial</brief_title>
	<detailed_description>The Objective trial compare efficacy , secondarily , safety effectiveness pre-procedural use Gp IIb/IIIa inhibitor eptifibatide comparison placebo patient diffuse CAD undergo multiple DES implantation .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Candidates study must meet following criterion : Male female able understand sign witness informed consent Age ≥ 18 yo Patients stable ( CCS 14 ) unstable angina pectoris ( recent anginal episode occur &gt; 48 hour procedure ) document silent ischemia Stable Hemodynamic condition ( systolic BP &gt; 100 HR &gt; 40 &lt; 100 ) . No clinical ECG change suggestive ongoing acute recent ( &lt; 48 hour ) myocardial infarction . Angiographic evidence de novo lesion &gt; 50 % require implantation two DES overlap total stent length &gt; 33 mm reference vessel diameter 2.5 4.0 mm ( visual estimation ) one coronary vessel . Multiple lesion vessel include least one lesion require implantation two DES overlap total stent length &gt; 33 mm . The definition multivessel disease require intention treat least two lesion ( least one characteristic report ) two different major epicardial segment . For example , presence lesion leave anterior descend artery obtuse marginal presence lesion right posterolateral branch diagonal branch qualify multivessel . The presence lesion leave anterior descend artery diagonal branch qualify multivessel . Bifurcation lesions ostial lesion include , least two DES overlap total stent length &gt; 33 mm implant branch . When treat diffuse lesion vessel , overlap stenting recommend high pressure ( &gt; 14 atm postdilation ) overlap zone . There maximum stent length treat one coronary vessel . Female sex childbearing potential Age &lt; 18 year Ongoing recent episode ( &lt; 48 hour ) unstable coronary artery disease ( include STelevation nonSTelevation acute coronary syndrome ) Administration GP IIb/IIIa inhibitor previous 2 week Serum creatinine &gt; 2.5 mg/dl creatinine clearance &lt; 40mL/min Ongoing serious bleed bleed diathesis Previous stroke last 6 month Major surgery within previous 6 week Platelet count &lt; 100,000 per mm3 Ejection Fraction 30 % The patient know hypersensitivity contraindication aspirin , heparin , clopidogrel , sensitivity contrast adequately premedicated . Hemodynamic instability ( systolic blood pressure &lt; 100 mm Hg ; heart rate &lt; 40 bpm &gt; 100 bpm ; complex ventricular arrhythmia ; AV block ) require balloon counterpulsation inotropic support . The patient simultaneously participate another device drug study . Patient must complete followup phase previous study least 30 day prior enrolment study . Positive clinical history intracranial neoplasia , AV malformation , aneurysm . INR ≥ 2.0 prothrombin time 1.2 time upper limit normality Clinically manifest reduce liver function Programmed surgery within six month Angiographic DES implantation chronic total occlusion treatment instent restenosis . Treatment lesion operator feel necessary usage rotactional atherectomy Vessel size &lt; 2.25 mm &gt; 5 mm ( visual estimation ) . Previous implantation bare/DES target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Eptifibatide</keyword>
	<keyword>IV eptifibatide</keyword>
	<keyword>GP IIB/IIIA inhibitor</keyword>
	<keyword>DES stent</keyword>
</DOC>